MAUDE Adverse Event Report: MICROVENTION, INC. LVIS; INTRACRANIAL COIL-ASSIST STENT

Model Number	212525-LVIS-D-PMA
Medical Device Problem Code	Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes	Headache (1880); Hemorrhage/Blood Loss/Bleeding (1888); High Blood Pressure/ Hypertension (1908); Muscle Weakness/Atrophy (1967); Hydrocephalus (3272); Aneurysm expansion (4597); Reduced Blood Flow (4598)
Date of Event	02/16/2022
Type of Reportable Event	Serious Injury
Additional Manufacturer Narrative
Procedure/medical information review: a detailed medical review of procedure note dated (b)(6) 2022, was performed.As reported in the lvis pas study, data reviewed indicates that an mri of the brain was performed two days post procedure which showed numerous small acute bilateral supratentorial embolic infarcts, sah and intraventricular hemorrhage.The patient had acute worsening left sided weakness on two days post procedure.Diagnostic cerebral angiogram three days post procedure showed which demonstrated 1) acom aneurysm residual/recurrence and 2) mild luminal irregularities in the distal aca branch vessels possibly due to mild distal aca vasospasm.The patient underwent retreatment procedure of stent-assisted coil embolization of acom aneurysm residual/recurrence on four day post procedure, which was completed.Follow-up angiogram revealed near complete occlusion and the patient was in the neuro icu until ten days post procedure.The patient was discharged on eleven days post procedure.Based on a review of available data, no lvis d device malfunction was reported and/or no lvis d device malfunction was reported as the cause of the event.Investigation findings: without the return and physical evaluation of the device, the investigation cannot further examine if a condition existed that would have contributed to the reported event.Based on a review of the device¿s risk documentation, the reported event did not indicate there were the presence of any potential or new manufacturing, design, quality, or other systemic issues, or non-conformances.The complaint code is monitored through the trending process; corrective action is determined, as needed, through this process.Investigations of historic complaint files with similar complaint category coding are recorded in the complaint handling system; without the ability to perform an analysis of the device, this investigation cannot identify with certainty any potential root causes.Batch review: a search for non-conformances associated with this part/lot number combination did not reveal any production-related issues relevant to the complaint that occurred during manufacturing of the device.Complaint system review: there are no similar complaints based on the complaint category regarding this batch number from the last two years recorded in the complaint system at the time of this investigation.Ifu review (additional information can be found in the ifu): potential adverse events the following potential risks and complications associated with general anesthesia, cerebral angiography, intracranial catheterization, intracranial stent placement or intra-saccular coil deployment have been identified below: ¿ allergic reaction, including but not limited to: contrast dye, nitinol metal, and any other medications used during the procedure; ¿ aphasia ¿ blindness; ¿ cardiac arrhythmia; ¿ coil prolapsed or migration into normal vessel adjacent to aneurysm ¿ complications of arterial puncture including pain, local bleeding, local infection and injury to the artery, vein or adjacent nerves; ¿ cranial neuropathy; ¿ death; ¿ device fracture, migration or misplacement; ¿ dissection or perforation of the parent artery; ¿ headache; ¿ hemorrhage (i.E., intracerebral hemorrhage (ich), subarchnoid hemorrhage (sah), or retroperitoneal (or in other locations)); ¿ hemiplegia; ¿ hydrocephalus; ¿ infection; ¿ injury to normal vessel or tissue; ¿ ischemia; ¿ mass effect; ¿ myocardial infarction; ¿ neurological deficits; ¿ occlusion of non-target side branches; ¿ pseudo aneurysm formation; ¿ reactions to anti-platelet/anti-coagulant agents; ¿ reactions due to radiation exposure; ¿ reactions to anesthesia and related procedures; ¿ reactions to contrast agents; ¿ renal failure; ¿ aneurysm rupture; ¿ stenosis of stented segment; ¿ seizure; ¿ stent thrombosis; ¿ stroke or tia (transient ischemic attack); ¿ thromboembolic event (t/e); ¿ vasospasm; ¿ visual impairment.Warnings should unusual resistance be felt at any time during access or removal, the introducer/guide catheter/microcatheter and lvis device should be removed as a single unit.Applying excessive force during delivery or retrieval of the lvis device can potentially result in loss or damage to the device and delivery components.It is imperative to use the lvis device with compatible microcatheters.If repeated friction is encountered during lvis device delivery, verify microcatheter is not kinked or in extremely tortuous anatomy.Confirm that the microcatheter does not ovalize.Confirm that there is adequate sterile flush solution.Do not reposition the lvis device in the parent vessel without fully retrieving the device.The lvis device must be retrieved into the microcatheter and re-deployed at the desired target location or removed completely from the patient.Precautions exercise caution when crossing the deployed/detached lvis device with adjunctive devices such as guidewires, catheters, microcatheters or balloon catheters to avoid disrupting the device geometry and device placement.Directions for use 15.Advance the delivery wire to transfer the lvis device from within the introducer into the microcatheter.Warning: do not torque the delivery wire while advancing or retracting the lvis device.A torque device should not be used.16.Continue advancing the delivery wire into the microcatheter until the proximal tip of the delivery wire enters the introducer.Loosen the rhv locking ring, remove the introducer, and set it aside.Warning: do not apply undue force.If resistance is encountered at any point during lvis device delivery or manipulation, withdraw the unit and select a new lvis device.18.Position the lvis device for deployment by aligning the lvis implant distal radiopaque end markers approximately 7 mm past the aneurysm neck.Note: a proper push/pull technique, encompassing sufficient delivery wire push force, in addition to an opposing microcatheter withdrawal force, will facilitate properly deploying the lvis device to achieve full expansion and good vessel apposition.Note: slowly advancing the lvis device while adjusting the microcatheter position will ensure accurate deployment.Maintain simultaneous control of the lvis device and microcatheter in order to position and expand the device at the proper location.Caution: using a rapid microcatheter withdrawal technique to deploy the lvis device is not recommended and may result in device elongation.19.If lvis device positioning is not satisfactory, the lvis device may be recaptured and repositioned if it is not fully deployed.The lvis device may be recaptured until the point where the proximal end of the lvis device markers is aligned 3 mm proximally with the microcatheter distal marker band (approximately 80% deployed).Caution: if resistance is felt while recapturing the lvis device, do not continue to recapture the device.Withdraw the microcatheter slightly to unsheath the lvis device (without exceeding the recapture limit), and then attempt to recapture the lvis device.Caution: the lvis device must not be re-deployed more than three times.Note: the lvis device delivery wire should not be utilized as a guidewire after stent deployment.Do not torque the lvis device.A torque device should not be used.20.If lvis device positioning is satisfactory, carefully retract the microcatheter and advance the delivery wire together, to allow the lvis device to deploy across the neck of the aneurysm.Ensure the device proximal radiopaque end markers are approximately 7 mm proximal to the aneurysm neck to ensure an adequate landing zone.The lvis device will expand and total length may foreshorten up to 60% from its undeployed length (refer to tables 1) as it exits the microcatheter.Ensure microcatheter is retracted and clear from the proximal flared ends.Note: visualize and refer to the implant radiopaque end markers to maintain adequate implant length, approximately 7 mm on each side of the aneurysm neck or target location to ensure appropriate neck coverage.Warning: do not detach the lvis device if it is not properly positioned in the parent vessel.Observe the delivery wire distal tip to assure it remains within the desired location of the parent vessel.21.Prior to removing the delivery wire and if necessary, carefully position the microcatheter distal to the lvis device to maintain access through the lvis device.Remove and discard the delivery wire.Warning: the lvis device delivery wire should not be utilized as a guidewire.Do not torque the lvis device.A torque device should not be used.Investigation conclusion: a detailed medical review of the provided procedure note found that a post-procedure mri showed numerous small acute bilateral supratentorial embolic infarcts, sah, and intraventricular hemorrhage.Diagnostic cerebral angiogram showed acom aneurysm residual/recurrence, mild luminal irregularities in the distal aca branch vessels possibly due to mild distal aca vasospasm.The patient underwent retreatment procedure of stent-assisted coil embolization of the acom aneurysm residual/recurrence.Follow-up angiogram revealed near complete occlusion.Based on the review of available data, no lvis d device malfunction was reported and/or no lvis d device malfunction was reported as the cause of the reported event.
Event or Problem Description
It was reported for a patient enrolled in the lvis pas study: retreatment of target aneurysm.Event description: patient was treated for residual aneurysm.Date of index procedure: (b)(6) 2022 outcome: resolved without sequelae.Site reported relatedness: disease related, study procedure related, and study device related.Target aneurysm: patient presented on (b)(6) 2022 with sah h&h grade 2, fisher 2 secondary to ruptured right aca target aneurysm.Index procedure: patient underwent stent-assisted coil embolization of acom aneurysm.There were no complications during the procedure.Post index procedure course: ct head one day post procedure showed stable mild hydrocephalus.Mri brain two days post procedure showed numerous small acute bilateral supratentorial embolic infarcts, sah and intraventricular hemorrhage.Patient had acute worsening left sided weakness on two days post procedure.Diagnostic cerebral angiogram on three days post procedure showed: 1) acom aneurysm residual/recurrence and 2) mild luminal irregularities in the distal aca branch vessels possibly due to mild distal aca vasospasm.Retreatment procedure: patient underwent retreatment procedure of stent-assisted coil embolization of acom aneurysm residual/recurrence four days post procedure was completed.Follow-up angiogram revealed near complete occlusion.She was in the neuro icu nine days post procedure.The patient had slight motor deficits in the left lower extremity, no sensory deficits.She has had a headache, but it has been getting better and is minimal on the day of discharge eleven days post procedure, and was discharged to acute rehab.The patient was evaluated in er for an episode of hypertension secondary to baseline uncontrolled hypertension and patient only recently got started on new blood pressure medication.Patient also complained of a mild headache (2/10).Workup was consistent with her baseline ckd, and ct head showed no acute bleed.The patient felt improved vital stabilized and was discharged.
Event or Problem Description
Additional information received reported that an mri two days pre-procedure showed numerous scattered small acute bilateral supratentorial infarcts which are most likely embolic.Emr documentation refers to them as watershed strokes.The patient experienced left sided weakness, decreased activity tolerance, impaired balance and was discharged from the hospital to acute rehab to continue physical therapy, occupational therapy, monitoring and management of blood pressures.The patient did not receive any medications or further treatment for this event.In a ct head obtained by rehab on nine days post procedure, states "sequela of prior white matter infarcts supratentorially again identified without increase.
Additional Manufacturer Narrative
Additional information received and updated in b5.Describe event or problem for ¿a ct head obtained by rehab on nine days post procedure¿.

• Brand Name: LVIS
• Common Device Name: INTRACRANIAL COIL-ASSIST STENT
• Manufacturer (Section D): MICROVENTION, INC.; 35 enterprise; aliso viejo CA 92656
• Manufacturer Contact: terrence callahan ; 35 enterprise; aliso viejo, CA 92656 ; 7142478000
• MDR Report Key: 24470841
• Report Number: 2032493-2026-00134
• Device Sequence Number: 10126121
• Product Code: QCA
• UDI-Device Identifier: 00842429100882
• UDI-Public: (01)00842429100882(11)200326(17)230228(10)20032656F
• Combination Product (Y/N): N
• Initial Reporter State: ND
• Initial Reporter Country: US
• PMA/510(K) Number: P170013
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Device Implanted Year: 2022
• Serviced by Third Party (Y/N): Unknown
• Reporter Type: Manufacturer
• Report Source: Study,Health Professional,User Facility,Company Representative
• Initial Reporter Occupation: Physician
• Type of Report: Initial,Followup
• Report Date (Section B): 04/08/2026

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Operator of Device: Health Professional
• Device Expiration Date: 02/28/2023
• Device Model Number: 212525-LVIS-D-PMA
• Device Lot Number: 20032656F
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Was the Report Sent to FDA?: No
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 02/02/2026
• Supplement Date Received by Manufacturer: 03/11/2026
• Initial Report FDA Received Date: 02/27/2026
• Supplement Report FDA Received Date: 04/08/2026
• Was Device Evaluated by Manufacturer? (Y/N): No
• Date Device Manufactured: 03/26/2020
• Is the Device Labeled for Single Use? (Y/N): Yes
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• Usage of Device: Initial
• Patient Sequence Number: 1
• Outcome Attributed to Adverse Event: Required Intervention
• Patient Age: 60 YR
• Patient Sex: Female
• Patient Ethnicity: Non Hispanic
• Patient Race: Black Or African American